Medical oncology: Endocrine-therapy-related symptoms and breast cancer

Nature Reviews Clinical Oncology

Volumn 6, Issue 6, 2009, Pages 309-310

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ARTHRALGIA; ARTHROPATHY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOT FLUSH; HUMAN; MYALGIA; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; RISK REDUCTION; TREATMENT DURATION; VASOMOTOR DISORDER; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; METABOLISM; NEOPLASM; TUMOR RECURRENCE;

AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; JOINT DISEASES; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT;

EID: 68549133541     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.67     Document Type: Article

References (10)

1. Anderson, W. F., Chatterjee, N., Ershler, W. B. & Brawley, O. W. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and End Results database. Breast Cancer Res. Treat. 76, 27-36 (2002).
2. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002).
3. Buzdar, A. U., Coombes, R. C., Goss, P. E. & Winer, E. P. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112, 700-709 (2008).
4. The ATAC Trialists' Group. Comprehensive sideeffect profile of anastrozole and tamoxifen as ajuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol. 7, 633-643 (2006).
5. Early Breast Cancer Trialists' Collaborative Group. effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365, 1687-1717 (2005).
6. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
7. Petersen, S. L. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Dan. Med. Bull. 54, 112-139 (2007).
8. Perez-Soler, R. & Saltz, L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: Is there a silver lining? J. Clin. Oncol. 23, 5235-5246 (2005).
9. Schneider, B. P. et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26, 4672-4678 (2008).
10. Cuzick, J., Sestak, I., Cella, D. & Fallowfield, L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol. 9, 1143-1148 (2008).